Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Submission of intimation regarding issue of duplicate share certificates.
Regulatory Filings
2025-03-26 English
Submission of press release under Regulation 30 (LODR) Regulations, 2015.
Earnings Release Classification · 95% confidence The document is a press release dated January 31, 2025, announcing the unaudited financial results for the quarter and nine months ended December 31, 2024. It highlights key financial metrics such as revenue, profit before tax, profit after tax, and earnings per share with year-over-year growth percentages. The document includes management commentary and future outlook but does not contain detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report. The document is a standalone announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). The length is about 5510 characters, which is sufficient for a press release but not a full quarterly report. Therefore, the appropriate classification is Earnings Release (ER). Q3 2025
2025-01-31 English
Submission of intimation of loss of share certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to the stock exchange (BSE Limited) regarding the loss of share certificates and the issuance of duplicate share certificates. It references SEBI regulations and circulars related to share certificate handling. The content is an announcement of a corporate action related to share certificates, not a financial report, management discussion, or any other detailed report. The document length is short (2211 characters) and it serves as an official notification to the exchange. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-31 English
Submission of intimation of change in the address of keeping & Maintaining of book of accounts other than the registered office of the Company.
Regulatory Filings
2025-01-28 English
Submission of intimation of change in the address of the Corporate office of the Company.
Regulatory Filings
2025-01-28 English
Submission of newspaper publication of financial results for the quarter ended December 31, 2024.
Regulatory Filings
2025-01-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.